Maiwei (Shanghai) Biotechnology Co., Ltd
Initial public offering and listing on the science and Innovation Board
Announcement of issuance results
Sponsor (lead underwriter): Haitong Securities Company Limited(600837)
hot tip
The application of Maiwei (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Maiwei biotechnology", "issuer" or "company") for initial public offering of RMB common shares (A shares) (hereinafter referred to as "this offering") has been examined and approved by the stock listing committee of the science and Innovation Board of Shanghai Stock Exchange, It has been approved to register by China Securities Regulatory Commission (hereinafter referred to as "CSRC") (zjxk [2021] No. 3859). The sponsor and lead underwriter of this offering are Haitong Securities Company Limited(600837) (hereinafter referred to as " Haitong Securities Company Limited(600837) " or "sponsor (lead underwriter)"). The issuer's stock is abbreviated as "Maiwei biology", and its expansion is abbreviated as "Maiwei biology", with the stock code of 688062.
The issuance adopts directional placement to strategic investors (hereinafter referred to as "strategic placement") Offline inquiry placement to qualified offline investors (hereinafter referred to as "offline issuance") and online pricing issuance to social public investors holding non restricted A-Shares and non restricted depositary receipts in Shanghai market (hereinafter referred to as "online issuance").
The issuer and the recommendation institution (lead underwriter) comprehensively consider the issuer's fundamentals, the number of shares in this public offering, the issuer's industry, the valuation level of comparable listed companies, market conditions, demand for raised funds and underwriting risks, and negotiate to determine that the offering price is 34.80 yuan / share, the number of shares to be issued is 99.9 million, all of which are new shares, No transfer of old shares.
The initial strategic placement quantity of this issuance is 14.985 million shares, accounting for 15% of this issuance quantity. The subscription funds promised by the strategic investor have been fully remitted to the bank account designated by the sponsor (lead underwriter) within the specified time. The final number of strategic allotments in this issuance is 532338200 shares, accounting for 5.33% of the total issuance. The difference between the initial strategic allotment and the final strategic allotment is 9661618 shares, which are transferred back to offline issuance.
Before the launch of the online and offline call back mechanism, the number of offline shares issued was 77593618, accounting for 82.04% of the number issued after deducting the final strategic placement; The number of shares issued online was 16.983 million, accounting for 17.96% of the number issued after deducting the final strategic placement.
According to the callback mechanism announced in the announcement on the initial public offering of shares by Maiwei (Shanghai) Biotechnology Co., Ltd. and listing on the science and Innovation Board (hereinafter referred to as the "issuance announcement"), since the initial effective subscription multiple of online investors is 4333.57 times, more than 100 times, the issuer and the recommendation institution (lead underwriter) decided to start the callback mechanism for offline The scale of online issuance was adjusted, and 9.458 million shares were transferred back from offline to online. After the callback mechanism was launched, the final number of shares issued offline was 68135618 shares, accounting for 72.04% of the number issued after deducting the number of strategic placements, and the final number of shares issued online was 26441000 shares, accounting for 27.96% of the number issued after deducting the number of strategic placements. After the callback mechanism was launched, the final winning rate of online issuance was 0.03592675%.
The online and offline subscription and payment of this offering has been completed on January 6, 2022 (T + 2). 1、 Statistics on subscription of new shares
The sponsor (lead underwriter) has made statistics on the subscription of new shares issued online and offline according to the data provided by Shanghai Stock Exchange and China Clearing Shanghai Branch. The results are as follows:
(I) strategic placement
The strategic placement of this offering is composed of the follow-up investment of relevant subsidiaries of the sponsor, the special asset management plan established by the participation of senior managers and core employees of the issuer in this strategic placement. The follow-up investment institution is Haitong innovation Securities Investment Co., Ltd. (hereinafter referred to as "Haitong venture capital"), The special asset management plan established by the issuer's senior managers and core employees participating in the strategic placement is the collective asset management plan of Fucheng Haifutong Maiwei biological employees participating in the strategic placement of science and innovation board.
As of December 29, 2021 (T-3), all strategic investors have paid the subscription funds and the corresponding new share placement brokerage commission in full and on time (Haitong venture capital does not need to pay the new share placement brokerage commission). The recommendation institution (lead underwriter) has returned the excess amount of the initial contribution of the strategic investor exceeding the corresponding amount of the final allocated shares before January 10, 2022 (T + 4).
The subscription results of strategic investors are as follows:
Name of strategic investor number of allocated shares (shares) amount allocated (yuan) restricted period of new share placement brokerage
Commission (yuan)
Haitong innovation Securities Investment Co., Ltd. 2873563 9999992.40 0 24 months
company
Fucheng Haifutong Maiwei biological technician 2449819 85253701.20 426268.51 12 months
ICBC participates in the strategic placement of science and Innovation Board
Collective asset management plan
Total 5323382 185253693.60 426268.51
(II) online subscription of new shares
(1) Number of shares subscribed by online investors (shares): 25664298
(2) Subscription amount paid by online investors (yuan): 893117570.40
(3) Number of online investors giving up subscription (shares): 776702
(4) Subscription amount waived by online investors (yuan): 27029229.60
(III) offline subscription of new shares
(1) Number of shares subscribed by offline investors (shares): 68135618
(2) Subscription amount paid by offline investors (yuan): 237114906.40
(3) Number of offline investors giving up subscription (shares): 0
(4) Subscription amount waived by offline investors (yuan): 0.00
(5) Brokerage commission for placement of new shares paid by offline investors (yuan): 11855599.99
2、 Offline placement lottery results
According to the announcement on the IPO arrangement and preliminary inquiry of Maiwei (Shanghai) Biotechnology Co., Ltd. and the announcement on the IPO and listing of Maiwei (Shanghai) Biotechnology Co., Ltd. on the science and innovation board, On the morning of January 7, 2022 (T + 3), the issuer and the sponsor (lead underwriter) presided over the lottery winning ceremony of the lower limit sales account of Maiwei biological's initial public offering online at Haitang hall, the conference room on the fourth floor of Zijinshan Hotel, 778 Dongfang Road, Pudong, Shanghai.
The lottery ceremony was conducted in accordance with the principles of openness, fairness and impartiality. The process and results of the lottery have been notarized by Shanghai Oriental notary office. The winning results are as follows:
Last digit winning lot number
Last "1" digit 3
Securities investment funds and other partial share asset management products established by participating in the public offering of offline issuance and subscription of A-Shares of Maiwei biology, national social security fund, basic endowment insurance fund, enterprise annuity fund established in accordance with the measures for the administration of enterprise annuity fund If the mantissa of the subscription allotment number held by the placement objects such as insurance funds and QFII funds that meet the relevant provisions of the measures for the administration of the use of insurance funds is the same as the above number, it is the winning number.
A total of 2834 accounts participated in the offline placement and lottery in this issuance, and the number of accounts corresponding to 10% of the final allocated accounts (rounded up) is 284. According to the lottery results, all successful accounts have obtained the shares for this placement, and the sales restriction period is 6 months. The number of shares corresponding to this part of the account is 5656607 shares, accounting for 8.30% of the total offline issuance and 5.98% of the total public offering after deducting the number of strategic placement. Please refer to the "attached table: table of lottery results of offline placement" for the specific conditions of the placing objects who won the lottery in this offline lottery. 3、 Underwriting by the sponsor (lead underwriter)
The number of shares abandoned by online and offline investors is underwritten by the sponsor (lead underwriter). The number of shares underwritten by the sponsor (lead underwriter) is 776702 shares, and the underwriting amount is 27029229.60 yuan. The number of shares underwritten by the sponsor (lead underwriter) accounts for 0.78% of the total amount of this offering.
On January 10, 2022 (T + 4), the recommendation institution (lead underwriter) transferred the remaining stock underwriting funds, the funds raised from strategic placement and the funds raised from offline and online issuance to the issuer in accordance with the recommendation and underwriting agreement, after deducting the recommendation and underwriting fee and the brokerage commission for new share placement. The issuer submitted an application for share registration to China Clearing Shanghai Branch, Register the underwritten shares in the securities account designated by the sponsor (lead underwriter).
4、 Contact information of sponsor (lead underwriter)
If online and offline investors have any questions about the issuance results announced in this announcement, please contact the sponsor (lead underwriter) of this issuance.
Contact details are as follows:
Tel: 021-23219622, 021-23219496, 021-23219524, 021-23219904
Contact: capital market department
Issuer: sponsor (lead underwriter) of Maiwei (Shanghai) Biotechnology Co., Ltd.: Haitong Securities Company Limited(600837) January 10, 2022 (there is no text on this page, which is the announcement on the results of initial public offering and listing on the science and Innovation Board of Maiwei (Shanghai) Biotechnology Co., Ltd (seal page)
Issuer: Maiwei (Shanghai) Biotechnology Co., Ltd. (this page has no text, which is the seal page of the announcement on the results of the initial public offering of shares by Maiwei (Shanghai) Biotechnology Co., Ltd. and listing on the science and Innovation Board)
Sponsor (lead underwriter): Haitong Securities Company Limited(600837) mm / DD / yy
Attached table: lottery results of offline placement
The placing object is finally
No. offline investor name placing object name code allocation quantity restricted period (shares)
1 China Europe Fund Management Co., Ltd. China Europe exchange selects one-year closed operation hybrid fund, d890307796 25176 6-month Corporate Fund (fof-lof)
2 Europe Fund Management Co., Ltd. China Europe Rongyi steady one-year holding hybrid securities d890261380 27002 6-month corporate investment fund
3 China Europe Fund Management Co., Ltd. China Europe liability investment hybrid securities investment fund d890237284 27002 6-month company
4 China Europe Fund Management Co., Ltd. China Europe innovative growth flexible configuration hybrid securities investment d890130026 27002 6-month corporate capital fund
5. China Europe Fund Management Co., Ltd. China Europe Jiaze flexibly allocates hybrid securities investment fund d890117028 15805 6-month company fund
6 China Europe Fund Management Co., Ltd. China Europe data mining multi factor flexible configuration hybrid d890028279 27002 6-month corporate securities investment fund
7. China Europe Fund Management Co., Ltd. China Europe value intelligent return hybrid securities investment base d890807636 27002 6-month corporate gold
8 Dongfang Fund Management Co., Ltd. Dongfang theme selected hybrid securities investment fund d899901738 27002 6-month Co., Ltd
9 Dongfang Fund Management Co., Ltd. Dongfang growth income flexible allocation hybrid securities investment d890786173 5957 6-month capital fund Co., Ltd
10 Minsheng plus bank fund management Minsheng plus bank steady allocation 6-month holding period hybrid
